tbuckley/cabot-search huggingface dataset:
Long‐Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial
Authors: Marc C. Hochberg, John A. Carrino, Thomas J. Schnitzer, Ali Guermazi, David A. Walsh, Alexander White, Satoru Nakajo, Robert J. Fountaine, Anne Hickman, Glenn Pixton, Lars Viktrup, Mark T. Brown, Christine R. West, Kenneth M. Verburg
Journal: Arthritis & Rheumatology (2021)

To assess the long-term safety and 16-week efficacy of subcutaneous tanezumab in patients with hip or knee osteoarthritis (OA).This was a phase III randomized, double-blind, active treatment-controlled (using nonsteroidal antiinflammatory drugs [NSAIDs] as the active treatment control) safety trial of tanezumab (56-week treatment/24-week posttreatment follow-up) in adults who were receiving stable-dose NSAID therapy at the time of screening and who had Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function scores of ≥5; patient global assessment (PtGA) of OA of fair, poor, or very poor; history of inadequate pain relief with standard analgesics; and no history or radiographic evidence of prespecified bone/joint conditions beyond OA. Patients received oral naproxen, celecoxib, or diclofenac twice daily (NSAID group; n = 996) or tanezumab 2.5 mg (n = 1,002) or 5 mg (n = 998) subcutaneously every 8 weeks. Coprimary efficacy end points at week 16 were changes in WOMAC pain and physical function scores and changes in PtGA. The primary joint safety end point over 80 weeks comprised adjudicated rapidly progressive OA type 1 or 2, primary osteonecrosis, subchondral insufficiency fracture, or pathologic fracture. Mean values, least squares mean values, and least squares mean differences between groups (with 95% confidence intervals [95% CIs]) were calculated.Of 3,021 randomized patients, 2,996 received ≥1 treatment dose. Adverse events (AEs) were similar between patients treated with tanezumab 2.5 mg and those treated with NSAIDs, and were more prevalent in those treated with tanezumab 5 mg. Composite joint safety events were significantly more prevalent with tanezumab 2.5 mg and tanezumab 5 mg than with NSAIDs (observation time-adjusted rate/1,000 patient-years 38.3 [95% CI 28.0, 52.5] and 71.5 [95% CI 56.7, 90.2], respectively, versus 14.8 [95% CI 8.9, 24.6]; P = 0.001 for tanezumab 2.5 mg versus NSAIDs; P < 0.001 for tanezumab 5 mg versus NSAIDs). Tanezumab 5 mg significantly improved pain and physical function but did not improve PtGA at week 16 when compared to NSAIDs; corresponding differences between the tanezumab 2.5 mg and NSAID groups were not statistically significant.In patients previously receiving a stable dose of NSAIDs, tanezumab administered subcutaneously resulted in more joint safety events than continued NSAIDs, with differences being dose dependent. Pain and physical function improved with both doses of tanezumab compared to NSAIDs, reaching statistical significance with tanezumab 5 mg at 16 weeks.
Faieza Jabeen Qasim
Authors: Asif Qasim
Journal: BMJ (2021)

At the age of 4, growing up in Nairobi, Faieza Jabeen Qasim had decided she was going to become a doctor, a commitment and passion that she held throughout her life

As the first Muslim pupil at Bradford Girls’ Grammar School, Faieza excelled in her studies and blazed a trail for bright children from all backgrounds. In spite of the devastating loss of her father, who died a few months before her A level exams, she achieved A grades, with the highest biology A level mark in the UK, and received the Biology Council National Award.

She went up to Newnham …
Involving Pregnant Individuals in Clinical Research on COVID-19 Vaccines
Authors: Diana W. Bianchi, Lisa Kaeser, Alison N. Cernich
Journal: JAMA (2021)

Ai-ris Y. Collier, MD; Katherine McMahan, MS; Jingyou Yu, PhD; Lisa H. Tostanoski, PhD; Ricardo Aguayo, BS; Jessica Ansel, NP; Abishek Chandrashekar, MS; Shivani Patel, BA; Esther Apraku Bondzie, BA; Daniel Sellers, BS; Julia Barrett, BS; Owen Sanborn, BS; Huahua Wan, MS; Aiquan Chang, BA; Tochi Anioke, BS; Joseph Nkolola, PhD; Connor Bradshaw, BS; Catherine Jacob-Dolan, BS; Jared Feldman, BS; Makda Gebre, MSc; Erica N. Borducchi, PhD; Jinyan Liu, PhD; Aaron G. Schmidt, PhD; Todd Suscovich, PhD; Caitlyn Linde, PhD; Galit Alter, PhD; Michele R. Hacker, ScD; Dan H. Barouch, MD, PhD
Proof-of-Principle Demonstration of Direct Metabolic Imaging Following Myocardial Infarction Using Hyperpolarized 13C CMR
Authors: Andrew Apps, Justin Y.C. Lau, Jack J.J.J. Miller, Andrew Tyler, Liam A.J. Young, Andrew J.M. Lewis, Gareth Barnes, Claire Trumper, Stefan Neubauer, Oliver J. Rider, Damian J. Tyler
Journal: JACC. Cardiovascular imaging (2021)
David Oliver: Wider health determinants aren’t just for pandemics
Authors: David Oliver
Journal: BMJ (2021)

Health politics are dominated by the power of the immediate. Future health gains through long term policies are easier to ignore than what happens now. The truism that we need to rebalance priorities away from reacting to sickness towards preventing ill health, tackling inequalities, maximising wellbeing, or helping people live better with long term conditions has become an orthodoxy. But the rhetoric is rarely matched by policy levers and investment big enough to do the job. We haven’t put our money where our mouth is.

Rapid access to urgent and emergency care, responsive primary care services for patients with immediate needs, and shorter waits for planned investigations and procedures always seem to dominate headlines. Political efforts to improve these are more likely to deliver measurable improvements within the lifespan of a parliament or politician. Bad …
Are we diagnosing too late? RAG deficiency in young adults with end organ damage
Authors: Tara Saco, Christoph Geier, David Buchbinder, Joseph Hernandez, Svetlana Sharapova, Alexis Cochino, Tomas Milota, Elema Latysheva, Emma Westerman-Clark, Olajumoke Fadugba, Emma Morris, Michael Albert, Dimana Dimitrova, Despina Moshous, Jennifer Kanakry, Steven Holland, Jean-Pierre de Villartay, Ravishankar Sargur, Luigi Notarangelo, Jolan Walter
Journal: Journal of Allergy and Clinical Immunology (2021)
Laxative Use and Risk of Dyskalemia in Patients with Advanced CKD Transitioning to Dialysis
Authors: Keiichi Sumida, Ankur A. Dashputre, Praveen K. Potukuchi, Fridtjof Thomas, Yoshitsugu Obi, Miklos Z. Molnar, Justin D. Gatwood, Elani Streja, Kamyar Kalantar-Zadeh, Csaba P. Kovesdy
Journal: Journal of the American Society of Nephrology (2021)

Significance Statement Intestinal potassium excretion is increased in patients with advanced CKD. It is possible that this compensatory mechanism is enhanced by laxative use, but little is known about the association of laxative use with risk of dyskalemias in advanced CKD. In a cohort of 36,116 United States military veterans who transitioned to ESKD, the authors found that time-varying laxative use was significantly associated with lower risk of hyperkalemia (potassium &gt;5.5 mEq/L) but was not associated with risk of hypokalemia (potassium &lt;3.5 mEq/L) during the last year prior to ESKD. These findings suggest a putative role of constipation in potassium disarrays and also support (with a careful consideration for risks and benefits) the therapeutic potential of laxatives for hyperkalemia management in advanced CKD. Background Patients with advanced CKD experience increased intestinal potassium excretion. This compensatory mechanism may be enhanced by laxative use; however, little is known about the association of laxative use with risk of dyskalemia in advanced CKD. Methods Our study population encompassed 36,116 United States veterans transitioning to ESKD from 2007 to 2015 with greater than or equal to one plasma potassium measurement during the last 1-year period before ESKD transition. Using generalized estimating equations with adjustment for potential confounders, we examined the association of time-varying laxative use with risk of dyskalemia ( i.e ., hypokalemia [potassium &lt;3.5 mEq/L] or hyperkalemia [&gt;5.5 mEq/L]) versus normokalemia (3.5–5.5 mEq/L) over the 1-year pre-ESKD period. To avoid potential overestimation of dyskalemia risk, potassium measurements within 7 days following a dyskalemia event were disregarded in the analyses. Results Over the last 1-year pre-ESKD period, there were 319,219 repeated potassium measurements in the cohort. Of these, 12,787 (4.0%) represented hypokalemia, and 15,842 (5.0%) represented hyperkalemia; the time-averaged potassium measurement was 4.5 mEq/L. After multivariable adjustment, time-varying laxative use (compared with nonuse) was significantly associated with lower risk of hyperkalemia (adjusted odds ratio [aOR], 0.79; 95% confidence interval [95% CI], 0.76 to 0.84) but was not associated with risk of hypokalemia (aOR, 1.01; 95% CI, 0.95 to 1.07). The results were robust to several sensitivity analyses. Conclusions Laxative use was independently associated with lower risk of hyperkalemia during the last 1-year pre-ESKD period. Our findings support a putative role of constipation in potassium disarrays and also support (with a careful consideration for the risk-benefit profiles) the therapeutic potential of laxatives in hyperkalemia management in advanced CKD.
Transcriptome-scale spatial gene expression in the human dorsolateral prefrontal cortex
Authors: Kristen R. Maynard, Leonardo Collado-Torres, Lukas M. Weber, Cedric Uytingco, Brianna K. Barry, Stephen R. Williams, Joseph L. Catallini, Matthew N. Tran, Zachary Besich, Madhavi Tippani, Jennifer Chew, Yifeng Yin, Joel E. Kleinman, Thomas M. Hyde, Nikhil Rao, Stephanie C. Hicks, Keri Martinowich, Andrew E. Jaffe
Journal: Nature Neuroscience (2021)
Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer
Authors: Huifang Chen, Jiameng Yao, Rujuan Bao, Yu Dong, Ting Zhang, Yanhua Du, Gaoyang Wang, Duan Ni, Zhenzhen Xun, Xiaoyin Niu, Youqiong Ye, Hua-Bing Li
Journal: Molecular Cancer (2021)

The four major RNA adenosine modifications, i.e., m
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
Authors: Peter Borchmann, Annette Plütschow, Carsten Kobe, Richard Greil, Julia Meissner, Max S Topp, Helmut Ostermann, Judith Dierlamm, Johannes Mohm, Julia Thiemer, Martin Sökler, Andrea Kerkhoff, Miriam Ahlborn, Teresa V Halbsguth, Sonja Martin, Ulrich Keller, Stefan Balabanov, Thomas Pabst, Martin Vogelhuber, Andreas Hüttmann, Martin Wilhelm, Josée M Zijlstra, Alden Moccia, Georg Kuhnert, Paul J Bröckelmann, Bastian von Tresckow, Michael Fuchs, Beate Klimm, Andreas Rosenwald, Hans Eich, Christian Baues, Simone Marnitz, Michael Hallek, Volker Diehl, Markus Dietlein, Andreas Engert
Journal: The Lancet Oncology (2021)
<i>miR-15a/16-1</i> deletion in activated B cells promotes plasma cell and mature B-cell neoplasms
Authors: Tomasz Sewastianik, Juerg R. Straubhaar, Jian-Jun Zhao, Mehmet K. Samur, Keith Adler, Helen E. Tanton, Vignesh Shanmugam, Omar Nadeem, Peter S. Dennis, Vinodh Pillai, Jianli Wang, Meng Jiang, Jianhong Lin, Ying Huang, Daniel Brooks, Mary Bouxsein, David M. Dorfman, Geraldine S. Pinkus, Davide F. Robbiani, Irene M. Ghobrial, Bogdan Budnik, Petr Jarolim, Nikhil C. Munshi, Kenneth C. Anderson, Ruben D. Carrasco
Journal: Blood (2021)
A Text-Book of Practical Medicine.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson’s disease
Authors: Rob Powers, Maryam Etezadi-Amoli, Edith M. Arnold, Sara Kianian, Irida Mance, Maxsim Gibiansky, Dan Trietsch, Alexander Singh Alvarado, James D. Kretlow, Todd M. Herrington, Salima Brillman, Nengchun Huang, Peter T. Lin, Hung A. Pham, Adeeti V. Ullal
Journal: Science Translational Medicine (2021)

A smartwatch-based sensing system measures tremor and dyskinesia, enabling remote monitoring and aiding medication titration in Parkinson’s disease.
Prostaglandin E<sub>2</sub> receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation
Authors: Yi Rang Na, Daun Jung, Michelle Stakenborg, Hyeri Jang, Gyo Jeong Gu, Mi Reu Jeong, Soo Youn Suh, Hak Jae Kim, Yoon Hey Kwon, Tae Sik Sung, Seung Bum Ryoo, Kyu Joo Park, Jong Pil Im, Ji Yong Park, Yun Sang Lee, Heonjong Han, Boyoun Park, Sungwook Lee, Daesik Kim, Ho Su Lee, Isabelle Cleynen, Gianluca Matteoli, Seung Hyeok Seok
Journal: Gut (2021)

Objective Dysfunctional resolution of intestinal inflammation and altered mucosal healing are essential features in the pathogenesis of inflammatory bowel disease (IBD). Intestinal macrophages are vital in the process of inflammation resolution, but the mechanisms underlying their mucosal healing capacity remain elusive. Design We investigated the role of the prostaglandin E 2 (PGE 2 ) receptor PTGER4 on the differentiation of intestinal macrophages in patients with IBD and mouse models of intestinal inflammation. We studied mucosal healing and intestinal epithelial barrier regeneration in Csf1r-iCre Ptger4 fl/fl mice during dextran sulfate sodium (DSS)-induced colitis. The effect of PTGER4 + macrophage secreted molecules was investigated on epithelial organoid differentiation. Results Here, we describe a subset of PTGER4-expressing intestinal macrophages with mucosal healing properties both in humans and mice. Csf1r-iCre Ptger4 fl/fl mice showed defective mucosal healing and epithelial barrier regeneration in a model of DSS colitis. Mechanistically, an increased mucosal level of PGE 2 triggers chemokine (C-X-C motif) ligand 1 (CXCL1) secretion in monocyte-derived PTGER4 + macrophages via mitogen-activated protein kinases (MAPKs). CXCL1 drives epithelial cell differentiation and proliferation from regenerating crypts during colitis. Specific therapeutic targeting of macrophages with liposomes loaded with an MAPK agonist augmented the production of CXCL1 in vivo in conditional macrophage PTGER4-deficient mice, restoring their defective epithelial regeneration and favouring mucosal healing. Conclusion PTGER4 + intestinal macrophages are essential for supporting the intestinal stem cell niche and regeneration of the injured epithelium. Our results pave the way for the development of a new class of therapeutic targets to promote macrophage healing functions and favour remission in patients with IBD.
Cell type–specific microRNA therapies for myocardial infarction
Authors: Bohao Liu, Bryan Wang, Xiaokan Zhang, Roberta Lock, Trevor Nash, Gordana Vunjak-Novakovic
Journal: Science Translational Medicine (2021)

Current interventions fail to recover injured myocardium after infarction and prompt the need for development of cardioprotective strategies. Of increasing interest is the therapeutic use of microRNAs to control gene expression through specific targeting of mRNAs. In this Review, we discuss current microRNA-based therapeutic strategies, describing the outcomes and limitations of key microRNAs with a focus on target cell types and molecular pathways. Last, we offer a perspective on the outlook of microRNA therapies for myocardial infarction, highlighting the outstanding challenges and emerging strategies.
Public Attitudes About COVID-19 in Response to President Trump's Social Media Posts
Authors: Dominic Arjuna Ugarte, William G. Cumberland, Lidia Flores, Sean D. Young
Journal: JAMA Network Open (2021)

This cross-sectional study examines public beliefs about the coronavirus disease 2019 (COVID-19) pandemic in response to President Trump's social media posts during and after his infection with the virus.
RETRACTED: Tumor cell-secreted exosomal miR-22-3p inhibits transgelin and induces vascular abnormalization to promote tumor budding
Authors: Yaju Feng, Lumeng Wang, Ting Wang, Ying Li, Qingqing Xun, Renya Zhang, Lin Liu, Lei Li, Wei Wang, Yixuan Tian, Lili Yang, Xiao Zhi, Bijiao Zhou, Xin Chen, Tao Sun, Yanrong Liu
Journal: Molecular Therapy (2021)

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the editor-in-chief. The editor-in-chief was informed of evidence for image duplication in identical or altered fashion in Figures 3A and 8D, as well as undisclosed reuse of an image in Figure 5B from a previous article in Cell Death & Disease (https://doi.org/10.1038/s41419-018-0902-5), in a PubPeer thread: https://pubpeer.com/publications/F5B591481C516F4CE42C7925AC48E9. Image analysis performed by the journal's editorial office confirmed these findings. This reuse (and in part misrepresentation) of data without appropriate attribution represents a severe abuse of the scientific publishing system.
Intensive Infection Control at a Canadian Tertiary Allergy and Clinical Immunology Clinic during COVID-19 to Provide Crucial Services
Authors: Jodi Valois, Hoang Pham, Derek Lanoue, Tim Olynych, William Yang
Journal: Journal of Allergy and Clinical Immunology (2021)

Several groups have made recommendations for adjustments during COVID-19 to facilitate the care of urgent/high-risk patients. Here we describe our Canadian multi-allergist tertiary allergy & clinical immunology clinic's observational data with intensive infection control measures to provide crucial services. After instituting an intensive infection control protocol, we measured the daily number of patients seen (virtually and in-person), skin tests, target biologic therapy (TBT), venom (VIT) and allergy immunotherapy (AIT) administered as well as adverse safety events (allergy related and viral transmission related). Our protocol consisted of scheduling in-person visits by appointment-only, health screening during the reminder call (ensuring no COVID-19 symptoms, exposures, and recent high-risk travel history) and before clinic entry, providing obligatory hand sanitizer and mask at the door, scanning body temperature, disinfecting rooms in-between patients, daily deep cleaning after-hours, donning full personal protective equipment for any direct patient care, and performing spirometry in outdoor tents with plexiglass. AIT patients waited in their own vehicle, if possible, to be directly monitored by staff for 30 minutes to maximize physical distancing. For any concerns, patients immediately called over front door staff or honked their car horn. Since the pandemic, we provided virtual care and accommodated over 18,000 patients. On average per day, there were 25 new teleconsults, 12 skin tests, 40 TBT, 30 VIT, and 80 AIT patients. There have been no adverse safety events. By adopting intensive infection control measures, we can optimize reduction of viral transmission and maintain crucial allergy services to keep high-risk allergic conditions under control.
Efficacy And Safety Of Budesonide Oral Suspension In A Pediatric Population: Pooled Data From A Phase 2 And Phase 3 Trial In Patients With Eosinophilic Esophagitis
Authors: Sandeep Gupta, Vincent Mukkada, Evan Dellon, Benjamin Gold, Margaret Collins, David Katzka, Gary Falk, Lan. Lan, Nirav Desai, James Williams, Ikuo Hirano
Journal: Journal of Allergy and Clinical Immunology (2021)
Response to: ‘Correspondence on ‘Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden’’ by Zervou<i>et al</i>
Authors: Viktor Molander, Johan Askling
Journal: Annals of the Rheumatic Diseases (2021)

Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou et alWe thank the authors for their interest 1 in our article 'Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden' 2 , and for their effort in identifying genetic factors involved in the pathogenesis of both rheumatoid arthritis (RA) and venous thromboembolism (VTE).As the authors suggest, identification of additional genetic loci associated with both diseases would be another important step in understanding the reasons behind the increased VTE risk in RA and might also help in identifying patients at particularly increased risk of VTE.
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial
Authors: Conor E. Steuer, Opeyemi A. Jegede, Suzanne E. Dahlberg, Heather A. Wakelee, Steven M. Keller, William J. Tester, David R. Gandara, Stephen L. Graziano, Alex A. Adjei, Charles A. Butts, Suresh S. Ramalingam, Joan H. Schiller
Journal: Journal of Thoracic Oncology (2021)
Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
Authors: Lawrence Eichenfield, Carsten Flohr, Robert Sidbury, Zsuzsanna Szalai, Ryszard Galus, Zhirong Yao, Hidetoshi Takahashi, Sébastien Barbarot, Claire Feeney, Fan Zhang, Marco DiBonaventura, Ricardo Rojo, Hernan Valdez, Gary Chan
Journal: Journal of Allergy and Clinical Immunology (2021)
Researchers must contribute to responsible reporting of suicide
Authors: Duleeka Knipe, Keith Hawton, Mark Sinyor, Thomas Niederkrotenthaler
Journal: BMJ (2021)

In their editorial on trends in suicide in the covid-19 pandemic, John and colleagues discuss the role of the media in preventing suicide.1 We would like to add that academics themselves need to contribute to responsible reporting through carefully described research findings, including in relation to covid-19.

Research has shown the potentially harmful effect of news reporting of suicide deaths on population suicide rates.2 Accordingly, media guidelines for reporting on suicide exist.345 These typically target …
Radial Approach for Primary Percutaneous Coronary Intervention: Ready for Prime Time?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily reflect the views of JACC or the American College of Cardiology.
Authors: Olivier F. Bertrand, Tejas Patel
Journal: Journal of the American College of Cardiology (2012)
Abstract 14120: PKCd, but not PKCa, Regulates Spontaneous Firing of the Cardiac Pacemaker
Authors: Tatiana M Vinogradova, Edward G Lakatta
Journal: Circulation (2013)

Spontaneous beating of the heart is controlled by spontaneous firing of sinoatrial node cells (SANC) and is linked to rhythmic, submembrane local Ca2+ releases (LCR) from the sarcoplasmic reticulum...
Mitochondrial uncoupler SHC517 reverses obesity in mice without affecting food intake
Authors: Sing-Young Chen, Martina Beretta, Stephanie J. Alexopoulos, Divya P. Shah, Ellen M. Olzomer, Stefan R. Hargett, Elizabeth S. Childress, Joseph M. Salamoun, Isabella Aleksovska, Ariane Roseblade, Charles Cranfield, Tristan Rawling, Kate G.R. Quinlan, Margaret J. Morris, Simon P. Tucker, Webster L. Santos, Kyle L. Hoehn
Journal: Metabolism (2021)